The DOI matches its Crossref record.
Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of Migraine
Abstract
Rizatriptan is a potent, oral, 5‐HT 1B/1D agonist with more rapid absorption and higher bioavailability than oral sumatriptan. It was postulated that this would result in more rapid onset of effect. This randomized, double‐blind, triple‐dummy, parallel‐groups study compared rizatriptan 5 mg, rizatriptan 10 mg, sumatriptan 100 mg, and placebo in 1268 outpatients treating a single migraine attack. Headache relief rates after rizatriptan 10 mg were consistently higher than sumatriptan at all time points up to 2 hours, with significance at 1 hour (37% versus 28%, P =0.010). All active agents were significantly superior to placebo with regard to headache relief and pain freedom at 2 hours ( P ≤0.001). The primary efficacy endpoint of time to pain relief through 2 hours demonstrated that, after adjustment for age imbalance, rizatriptan 10 mg had earlier onset than sumatriptan 100 mg ( P =0.032; hazard ratio 1.21). Rizatriptan 10 mg was also superior to sumatriptan on pain‐free response ( P =0.032), reduction in functional disability ( P =0.015), and relief of nausea at 2 hours ( P =0.010). Significantly fewer drug‐related clinical adverse events were reported after rizatriptan 10 mg (33%, P =0.014) compared with sumatriptan 100 mg (41%). We conclude that rizatriptan 10 mg has a rapid onset of action and relieves headache and associated symptoms more effectively than sumatriptan 100 mg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Guidelines for Controlled Trials of Drugs in Migraine: Second Edition
International Headache Society Clinical Trials Subcommittee, Tfelt-Hansen, P., Block, G., Dahlöf, C., Diener, H.-C., Ferrari, M., Goadsby, P., Guidetti, V, Jones, B., Lipton, R., et al. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00117.x · Cited by 698
Self-citationFerrari, M., Goadsby, P., Roon, K., & Lipton, R. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00404.x · Cited by 605
Defeating migraine pain with triptans: A race against the development of cutaneous allodynia
Burstein, R., Collins, B., & Jakubowski, M. (2004) · Annals of Neurology · doi:10.1002/ana.10786 · Cited by 602
Triptans in Migraine: A Comparative Review of Pharmacology, Pharmacokinetics and Efficacy
Tfelt-Hansen, P., De Vries, P., & Saxena, P. R. (2000) · Drugs · doi:10.2165/00003495-200060060-00003 · Cited by 529
Self-citation
Metadata
- Authors
- Tfelt‐Hansen, P., Teall, J., Rodriguez, F., Giacovazzo, M., Paz, J., Malbecq, W., Block, G. A., Reines, S. A., & Visser, W. H.
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 1998-11
- Volume
- 38
- Issue
- 10
- Pages
- 748-755
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W1966324558
- Cited by
- 192
- References
- 0
- FWCI
- 16.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of Migraine. https://app.cochat.ai/papers/10.1046/j.1526-4610.1998.3810748.x
- The paper
- Tfelt‐Hansen, P., Teall, J., Rodriguez, F., Giacovazzo, M., Paz, J., Malbecq, W., Block, G. A., Reines, S. A., & Visser, W. H. (1998). Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of Migraine. Headache: The Journal of Head and Face Pain. https://doi.org/10.1046/j.1526-4610.1998.3810748.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.